National Interest on MSN4d
The A-4 Skyhawk Is A Movie Star—And A Great Fighter Jet, Too
In Top Gun—undoubtedly the most culturally relevant military aviation film ever made—the A-4 pops up multiple times.
Q4 2024 Imunon Inc Earnings Call
Stacy Lindborg; Independent Director; Imunon Inc. Presentation. Operator. Good morning. My name is Mike, and I will be your operator today. At this time, I would lik ...
Imunon, Inc. (IMNN) Q4 2024 Earnings Call Transcript
Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...
National Interest on MSN4d
A Most Unwanted Plane: Canada’s CF-5 Freedom Fighter
Canada’s experience with the CF-5 is a warning to the United States about what happens when pinching pennies in the defense budget takes precedence over strategic sense.
The National Interest4d
A Most Unwanted Plane: Canada’s CF-5 Freedom Fighter
To maintain a reliable deterrent against the Soviets in the Cold War, the Canadians routinely purchased weapons and other systems from their American partners. Some were phenomenal hits, such as ...
The Aviationist4d
OA-1K Officially Dubbed Skyraider II, Honoring the Legendary A-1 Skyraider
AFSOC leaders broke the news today at the Special Air Warfare Symposium. The name pays tribute to the battle-tested legacy of ...
Air Force’s newest plane, the Skyraider II, honors a legendary aircraft
The Skyraider II is the latest aircraft to pay homage to a legendary plane. The original A-1 Skyraider flew from 1946 to the ...
Yahoo Finance4d
IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
LAWRENCEVILLE, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial ...